natgillin/translations-raw huggingface dataset:
Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins. 
O učinku hemodialize pri zdravljenju prevelikega odmerjanja aripiprazola ni podatkov, vendar je malo verjetno, da bi koristila, ker je aripiprazol izrazito vezan na beljakovine v plazmi.
Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. 
Zdravilo Aripiprazol Mylan Pharma je indicirano za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied. 
Pričakovati je mogoče, da imajo drugi močni zaviralci CYP2D6, npr. fluoksetin in paroksetin, podobne učinke, zato je treba odmerjanje podobno zmanjšati.
Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied. 
Pri sočasni uporabi aripiprazola in drugih induktorjev CYP3A4 (npr. rifampicin, rifabutin, fenitoin, fenobarbital, primidon, efavirenz, nevirapin in šentjanževka) je mogoče pričakovati, da imajo drugi podobne učinke, zato je treba odmerjanje podobno zvečati.
Mylan Healthcare Sp. z.o.o. 
Polska Mylan Healthcare Sp. z.o.o.
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g. indinavir, ritonavir) 
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz, npr. indinavir, ritonavir),
Magyarország Mylan EPD Kft Tel: + 36 1 465 2100 
Mylan EPD Kft Tel: + 36 1 465 2100
There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. 
Poročali so o agitaciji, hipertoniji, hipotoniji, tremorju, somnolenci, respiratorni stiski in motnjah hranjenja.
Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. 
Ni natančnih ocen tveganja za hiperglikemične neželene učinke med prejemniki aripiprazola in drugih atipičnih antipsihotikov, ki bi omogočale neposredno primerjavo.
Potential for other medicinal products to affect aripiprazole 
Možnost vpliva drugih zdravil na aripiprazol
Taking Aripiprazole Mylan Pharma with some medicines may mean the doctor will need to change your dose of Aripiprazole Mylan Pharma or the other medicines. 
Če jemljete zdravilo Aripiprazol Mylan Pharma z nekaterimi drugimi zdravili, bo morda zdravnik moral spremeniti vaš odmerek zdravila Aripiprazol Mylan Pharma ali drugih zdravil.
Aripiprazole is excreted in human milk. 
Aripiprazol se izloča v materino mleko.
Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno z aripiprazolom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects. 
Ugotovljeno je, da so farmakokinetične lastnosti aripiprazola in dehidroaripiprazola pri bolnikih s hudo boleznijo ledvic podobne kot pri mladih zdravih preiskovancih.
Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing or reducing the symptoms. 
Z vami se bo pogovoril o načinih obvladovanja ali zmanjšanja simptomov.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol. 
Dejanske ocene po ocenjevalnih lestvicah (vključno s PANSS in lestvico ‘Montgomery-Asberg Depression Rating Scale'), ki so predstavljale sekundarne končne točke, so pokazale značilno izboljšanje v primerjavi s haloperidolom.
In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. 
V post-hoc analizi je bilo izboljšanje glede na placebo izrazitejše pri bolnikih s sočasno diagnozo motnje pomanjkanja pozornosti v primerjavi z bolniki brez te diagnoze, kjer razlike glede na placebo ni bilo.
4.7 Effects on ability to drive and use machines Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8). 
Aripiprazol ima blag do zmeren vpliv na sposobnost vožnje in upravljanje s stroji zaradi morebitnega vpliva na živčni sistem in vid, kot je sedacija, somnolenca, sinkopa, zamegljen vid in diplopija (glejte poglavje 4.8).
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. 
Aripiprazol morate uporabljati previdno pri bolnikih z znano srčnožilno boleznijo (anamnezo miokardnega infarkta ali ishemično boleznijo srca, srčnim popuščanjem ali prevodnimi motnjami), cerebrovaskularno boleznijo ali stanji, ki ustvarjajo nagnjenost k hipotenziji (dehidracija, hipovolemija in zdravljenje z antihipertenzivi) ali hipertenziji, vključno s pospešeno in maligno hipertenzijo.
• speech disorder, 
• motnje govora,
Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. 
Distonični simptomi vključujejo: spazem vratnih mišic, ki lahko povzroči stiskanje žrela, težave pri požiranju, težave pri dihanju in/ali protruzijo jezika.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'. 
Vsebnost natrija To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ‘'brez natrija''.
At steady state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma. 
V stanju dinamičnega ravnovesja predstavlja aktivni presnovek dehidroaripiprazol okrog 40 % AUC aripiprazola v plazmi.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension 
Žilne bolezni ortostatska hipotenzija venska tromboembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
It has been proposed that aripiprazole's efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors. 
Učinkovitost aripiprazola pri shizofreniji in bipolarni motnji I je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A
Greece or 
Grčija ali
• swelling of hands, ankles or feet, 
• zatekanje rok, gležnjev ali stopal,
Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. 
Poročali so o prirojenih anomalijah, vendar pa vzročne povezave z aripiprazolom niso dokazali.
• blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots 
• imate krvne strdke ali težave s krvnimi strdki v družini; antipsihotike namreč povezujejo z nastajanjem krvnih strdkov,
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). 
Klinični znaki MNS-a so hiperpireksija, mišična rigidnost, spremenjeno duševno stanje in znaki avtonomne nestabilnosti (nereden srčni utrip ali krvni tlak, tahikardija, čezmerno znojenje in motnje srčnega ritma).
These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). 
Med njimi so bili: od odmerka odvisni adrenokortikalni toksični učinki (kopičenje pigmenta lipofuscina in/ali izguba parenhimskih celic) pri podganah po 104 tednih odmerjanja od 20 do 60 mg/kg/dan (od 3- do 10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka) ter zvečana pogostnost adrenokortikalnih karcinomov in kombiniranih adrenokortikalnih adenomov/karcinomov pri podganjih samicah ob odmerjanju 60 mg/kg/dan (10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka).
Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. 
Uporabo aripiprazola so raziskovali tudi v s placebom nadzorovanem preskušanju dolgotrajnega vzdrževalnega zdravljenja.
Hyperglycaemia and diabetes mellitus 
Hiperglikemija in diabetes mellitus
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors. 
In vitro je imel aripiprazol veliko vezavno afiniteto za dopaminske receptorje D2 in D3 in za serotoninske receptorje 5-HT1A in 5-HT2A ter zmerno afiniteto za dopaminske receptorje D4, serotoninske receptorje 5-HT2C in 5-HT7, adrenergične receptorje alfa-1 in histaminske receptorje H1.
Cerebrovascular adverse reactions 
Cerebrovaskularni neželeni učinki
Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. 
Preprečevanje ponovitev maničnih epizod pri bipolarni motnji I: za preprečevanje ponovitev maničnih epizod pri bolnikih, ki so se zdravili z aripiprazolom samostojno ali v sklopu kombiniranega zdravljenja, se zdravljenje nadaljuje z istim odmerkom.
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. 
V kliničnem preskušanju pri zdravih preiskovancih je močan zaviralec CYP2D6 (kinidin) zvečal AUC aripiprazola za 107 %, Cmax pa se ni spremenila.
They are supplied in PA/Alu/PVC-Aluminium foil perforated blisters packed in cardboard box containing 14, 28, 56 or 98 tablets and 28 x 1 tablets (unit dose). 
Na voljo so v PA/Alu/PVC- aluminijastih perforiranih pretisnih omotih pakiranih v škatlah, ki vsebujejo po 14, 28, 56 ali 98, 28 x 1 tablet.
Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. 
Odmerek so po enem tednu povečali do 5 mg/dan, nato pa so ga do ciljnega odmerka povečevali za 5 mg/dan v tedenskih presledkih.
In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. 
V 60- do 89-tedenskem randomiziranem, dvojno slepem, s placebo kontroliranem preskušanju pri mladostnikih (n = 146; 13 - 17 let) s shizofrenijo je bila statistično pomembna razlika v stopnji ponovitev psihotičnih simptomov med skupino, ki je jemala aripiprazol (19,39 %), in skupino, ki je jemala placebo (37,50 %).
Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). 
Pri odmerkih, večjih od dnevnega odmerka 10 mg, večje učinkovitosti niso dokazali, so pa pri dnevnem odmerku 30 mg znatno pogostejši pomembni neželeni učinki, vključno z ekstrapiramidnimi simptomi, zaspanostjo, utrujenostjo in povečanjem telesne mase (glejte poglavje 4.8).
The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate. 
Po Kaplan-Meierjevi metodi izračunani deleži ponovitev katerekoli razpoloženjske epizode pri uporabi dodatnega zdravila so bili 16 % pri uporabi kombinacije aripiprazol + litij in 18 % pri uporabi kombinacije aripiprazol + valproat v primerjavi s 45 % pri kombinaciji placebo + litij ter 19 % pri kombinaciji placebo + valproat.
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. 
Med dodatnimi znaki so lahko zvišana kreatin-fosfokinaza, mioglobinurija (rabdomioliza) in akutna odpoved ledvic.
In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). 
V kliničnih preskušanjih niso ugotovili, da bi aripiprazol povzročil klinično pomembno povečanje telesne mase pri odraslih (glejte poglavje 5.1).
• increased blood levels of the hormone prolactin, 
• zvišane ravni hormona prolaktina v krvi,
For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days. 
Mediana časa do pojava je bila za bolnike, ki so prejemali aripiprazol, 30 dni, mediana trajanja pa 194 dni.
Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). 
Zdravilo Aripiprazol Mylan Pharma je indicirano za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I ter za preprečevanje novih maničnih epizod pri odraslih bolnikih, ki so doživljali pretežno manične epizode, ki so bile odzivne na zdravljenje z aripiprazolom (glejte poglavje 5.1).
Aripiprazole Mylan Pharmais used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. 
Zdravilo Aripiprazol Mylan Pharma uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). 
Pri bolnikih, ki so prejemali odmerek 30 mg, so bili najpogostejši neželeni učinki ektrapiramidne motnje (28,3 %), zaspanost (27,3 %), glavobol (23,2 %) in navzea (14,1 %).
• allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives), 
• alergijska reakcija (npr. oteklost ust, jezika, obraza in žrela, srbenje, izpuščaj);
It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. 
Pomembno je, da zdravniki, ki zdravilo predpišejo, bolnike ali njihove skrbnike posebej vprašajo, ali se je pri njih med zdravljenjem z apriprazolom pojavila povečana želja po hazardiranju, povečan spolni nagon, kompulzivno nakupovanje, kompulzivno prenajedanje ali drugi impulzi.
Close supervision of high-risk patients should accompany antipsychotic treatment. 
Med antipsihotičnim zdravljenjem je treba bolnike z visokim tveganjem skrbno nadzirati.
Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. 
Ni dokazano, da bi bili dnevni odmerki nad 15 mg učinkovitejši, a posameznim bolnikom lahko koristijo večji odmerki.
If weight gain is clinically significant, dose reduction should be considered (see section 4.8). 
Če je povečanje telesne mase klinično pomembno, je treba razmisliti o zmanjšanju odmerka (glejte poglavje 4.8).
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1). 
V kliničnih preskušanjih in v obdobju trženja aripiprazola so za odobrene indikacije opazili povečanje in zmanjšanje serumskega prolaktina v primerjavi z izhodiščnimi vrednostmi (poglavje 5.1).
The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. 
Delež smrti je bil v skupini z aripiprazolom 3,5 % in v skupini s placebom 1,7 %.
Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group. 
Po jemanju aripiprazola je bilo 8. teden vidno izboljšanje s spremembo od izhodiščne vrednosti rezultata TTS-YGTSS za 13,35 točk pri skupini z nizkim odmerkom (5 ali 10 mg) in za 16,94 točk pri skupini z visokim odmerkom (10 ali 20 mg) v primerjavi z izboljšanjem za 7,09 točk pri skupini, ki je prejemala placebo.
• cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure 
• imate srčnožilne bolezni (bolezni srca in ožilja), srčnožilne bolezni v družini, možgansko kap ali »malo« kap, nenormalen krvni tlak,
In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. 
Pri starejših bolnikih z demenco so med jemanjem aripiprazola poročali o več smrtnih primerih.
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole. 
Populacijska farmakokinetična analiza ni pokazala klinično pomembnih učinkov kajenja na farmakokinetiko apiprazola.
Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia. 
Pri bolnikih s tveganjem za aspiracijsko pljučnico je treba aripiprazol uporabljati previdno.
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. 
Učinek zdravil iz te skupine (‘Class Effect') - V prvih nekaj dneh zdravljenja se lahko pri dovzetnih posameznikih pojavijo simptomi distonije, podaljšane nenormalne kontrakcije mišičnih skupin.
For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days. 
Mediana časa do pojava je bila za bolnike, ki so prejemali aripiprazol, 42 dni, mediana trajanja pa 34 dni.
Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. 
Podobno je bila po sočasni uporabi karbamazepina geometrična sredina Cmax dehidroaripiprazola za 69 % nižja, njegova AUC pa za 71 % nižja kot po zdravljenju s samim aripiprazolom.
Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8). 
Aripiprazol je zato treba previdno uporabljati pri bolnikih, ki imajo anamnezo konvulzivnih motenj ali imajo bolezni, povezane s konvulzivnimi napadi (glejte poglavje 4.8).
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone. 
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4, in peroralnega aripiprazola pri bolnikih s shizofrenijo in shizoafektivno motnjo je bila geometrična sredina Cmax za 68 % nižja, AUC pa za 73 % nižja kot po uporabi samega aripiprazola (30 mg).
Quinidine and other CYP2D6 inhibitors 
Kinidin in drugi močni zaviralci CYP2D6
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania). 
Dodatno zdravljenje z aripiprazolom se je izkazalo za boljše od placeba tudi pri sekundarnem merilu izida, lestvici resnosti bolezni CGI-BP za manijo.
• anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital) 
• antikonvulzive, ki se uporabljajo za zdravljenje epilepsije (kot so karbamazepin, fenitoin, fenobarbital),
Carbamazepine and other CYP3A4 inducers 
Karbamazepin in drugi močni induktorji CYP3A4
In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. 
V kliničnih preskušanjih pri mladostnikih z bipolarno manijo so po 4 tednih dokazali, da je zdravljenje z aripiprazolom povezano s povečanjem telesne mase.
The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. 
Med opaženimi znaki in simptomi, ki so lahko medicinsko pomembni, so letargija, zvišan krvni tlak, somnolenca, tahikardija, navzea, bruhanje in driska.
Pathological gambling and other impulse control disorders Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see section 4.4). 
Patološko hazardiranje in druge motnje nadzora impulzov Pri bolnikih, ki se zdravijo z apriprazolom, se lahko pojavi patološko hazardiraje, povečan spolni nagon, kompulzivno nakupovanje in kompulzivno prenajedanje (glejte poglavje 4.4).
• muscle disorder causing twisting movements (dystonia), 
• bolezen mišic, ki povzroča krčenje mišic (distonija),
If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered. 
Če se pri bolniku, ki se zdravi z aripiprazolom pojavijo znaki drugih ekstrapiramidnih simptomov, je treba razmisliti o zmanjšanju odmerka in o skrbnem kliničnem nadzoru bolnika.
If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). 
Če se pri bolniku, ki dobiva aripiprazol, pojavijo znaki in simptomi zapoznele diskinezije, je treba razmisliti o zmanjšanju odmerka ali prekinitvi zdravljenja (glejte poglavje 4.8).
When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations. 
Če so aripiprazol uporabili sočasno z valproatom, litijem ali lamotriginom, se koncentracije valproata, litija ali lamotrigina niso klinično pomembneje spremenile.
Hyperprolactinaemia Diabetic hyperosmolar coma Diabetic ketoacidosis 
Bolezni endokrinega sistema hiperprolaktinemija diabetična hiperosmolarna koma diabetična ketoacidoza